Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Radioterapia de hipofração para câncer de pulmão de células não pequenas localmente avançado

26 de outubro de 2026 atualizado por: Dong Qian, Anhui Provincial Hospital

Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial

Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.

Visão geral do estudo

Descrição detalhada

Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase II clinical trial.

Trial objective: To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.

Trial Design: To enroll 36 patients diagnosed with stage III locally advanced non-small cell lung cancer to receive hypofraction radiotherapy (18 patients receiving high dose of 60 (Gray, Gy) /15 (fraction, f) and 18 patients receiving low dose of 48Gy/12f) followed by 1-year maintenance of immune checkpoint inhibitors.

Inclusion Criteria: a. 18-70 years old; b. Eastern Cooperative Oncology Group (ECOG) 0-1; c. non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma; d. wild-type of driven genes; e. stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and Positron Emission Tomography (PET-CT); f. surgically unresectable or deny of surgery; g. signature of inform consent.

Exclusion Criteria: a. younger than 18 years old or older than 70 years old; b. ECOG>1; c. small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma; d. mutant type of driven genes; e. Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT; f. surgically resectable; g. no signature of inform consent.

Staging Examination before Radiotherapy: a. ECOG scoring. b. Cranial contrast MRI and PET-CT, or cranial contrast MRI (preferred), chest contrast CT, abdominal ultrasonography and bone scan. c. Bronchoscopy for centrally-located lung cancer. d. Staging examination is mandatory after inductive chemotherapy & chemotherapy with immunotherapy. e. Pulmonary function test.

Inductive therapy before radiotherapy: Chemotherapy or chemotherapy combined with immunotherapy is allowed as inductive therapy. Detailed regimen could refer to NCCN guidelines. Tyrosine kinase inhibitors are not allowed as inductive therapy.

Randomization: Patients would be randomly assigned to high dose group and low dose group using random number table method.

Radiotherapy CT simulation: 4-Dimensional CT (4D-CT) with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm. Thermal mask or vacuum bag is recommended.

Target Delineation: Considering hypofraction and involved field irradiation (IFI), only Internal Tumor Volume (ITV) should be delineated without the need to delineate Clinical Tumor Volume (CTV).

Delineation of ITV: ITV should include pulmonary gross tumor and metastatic mediastinal lymph nodes. PET-CT registration with simulation CT is recommended for patients with obstructive atelectasis. For patients with suspected mediastinal lymph nodes, Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is recommended.

Production of Planning Tumor Volume (PTV):

Low-dose Arm (48Gy/12f) PTV: PTV is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.

High-dose Arm (60Gy/15f) PTV: Planning Tumor Volume (PTV) is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.

The protection of OAR was given higher priority than the prescription dose coverage of PTV. The dose to PTV in adjacent to or abutting esophagus and spinal cord could be compromised with the lowest coverage rate of 90%.

Dosimetric Limitation:

Total Lung: V20<23%, Dmean<13Gy, V5<50%. Spinal Cord: Dmax<40Gy. Heart:V42<15cc, Dmax<48.9Gy in high-dose arm, V36.6<15cc, Dmax<42.5Gy in low-dose arm.

Great Vessels: V57<10cc,Dmax<65Gy in high-dose arm, V55.7<10cc,Dmax<62.9Gy in low-dose arm.

Esophagus: V45<2.5cc in high-dose arm, V40<2.5 cc in low-dose arm. Proximal Bronchial Tree: V55.5<5cc, Dmax<65Gy in high-dose arm, V52<5cc, Dmax<59Gy in low-dose arm.

Branchial Plexus: V48<3cc, Dmax<52.5Gy in high-dose arm, V37<3cc, Dmax<43Gy in low-dose arm.

Treatment Implementation: Radiotherapy is implemented every day. Cone-beam CT should utilized every day to minimize set-up error.

Concurrent Chemotherapy:For patients who have received over 4 cycles of inductive chemotherapy with or without immunotherapy, no concurrent chemotherapy is needed. For patients who had not received induction therapy or less than 4 cycles of inductive chemotherapy with or without immunotherapy, concurrent chemotherapy is needed to ensure 4 cycles of chemotherapy. Adenocarcinoma: Pemetrexed combined with platinum is recommended. Squamous-cell lung cancer: Etoposide combined with platinum is recommended. One month after completion of radiotherapy, chest CT and abdominal ultrasonography should be undertaken. After exclusion of disease progression and grade 2 or more radiation-induced pneumonitis, consolidative immunotherapy should be started. Durvalumab maintenance for one year is recommended.

Follow-up: Patients should be follow-up every three months right after the completion of radiotherapy to 3 years after radiotherapy. Then follow-up every half year is allowed to 5 years after radiotherapy. After 5 years, follow-up every year is appropriate. In follow-up, chest CT and abdominal ultrasonography should be implemented. Cranial MRI should be performed every half year for patients with adenocarcinoma. Bone scan should be undertaken every year for all patients.

Primary Endpoint: Rate of radiation-induced pneumonitis, esophagitis, central hilar structure injury rate, hematologic toxicity (CTCAE V4.0).

Secondary Endpoint: Median overall survival, 2-year overall survival rate, Median progression-free survival, 2-year progression-free survival, Objective response rate, Complete response rate, Partial response rate (RECIST v1.1).

Tipo de estudo

Intervencional

Inscrição (Real)

36

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Anhui
      • Hefei, Anhui, China
        • Anhui Provicial Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18-70 years old;
  • Eastern Cooperative Oncology Group (ECOG) 0-1;
  • Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
  • Wild-type of driven genes;
  • Stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
  • Surgically unresectable or deny of surgery;
  • Signature of inform consent.

Exclusion Criteria:

  • Younger than 18 years old or older than 70 years old;
  • ECOG>1;
  • Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
  • Mutant type of driven genes;
  • Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
  • Surgically resectable;
  • No signature of inform consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: High-dose Arm

Irradiation of 60Gy/15f is administered followed by one-year immunotherapy maintenance.

Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f with one-year immunotherapy maintenance.

Experimental: Low-dose Arm

Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.

Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/12f with one-year immunotherapy maintenance.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Rate of radiation-induced pneumonitis (CTCAE V4.0)
Prazo: 1 to 2 years

Rate of radiation-induced pneumonitis (CTCAE V4.0)

1 to 2 years
Rate of radiation-induced esophagitis (CTCAE V4.0)
Prazo: 1 to 2 years

Rate of radiation-induced esophagitis (CTCAE V4.0)

1 to 2 years
Rate of central hilar structure injury (CTCAE V4.0)
Prazo: 1 to 2 years

Rate of central hilar structure injury (CTCAE V4.0)

1 to 2 years
Rate of hematologic toxicity
Prazo: 1 to 2 years

Rate of hematologic toxicity

1 to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Median overall survival (RECIST 1.1)
Prazo: 1-2 year

Median overall survival (RECIST 1.1)

1-2 year
2-year overall survival rate (RECIST 1.1)
Prazo: 2 year

2-year overall survival rate (RECIST 1.1)

2 year
Median progression-free survival (RECIST 1.1)
Prazo: 1-2 year

Median progression-free survival (RECIST 1.1)

1-2 year
2-year progression-free survival rate (RECIST 1.1)
Prazo: 2 year

2-year progression-free survival rate (RECIST 1.1)

2 year
Objective response rate
Prazo: 3 months after radiotherapy

Objective response rate

3 months after radiotherapy
Complete response rate
Prazo: 3 months after radiotherapy

Complete response rate

3 months after radiotherapy
Partial response rate
Prazo: 3 months after radiotherapy

Partial response rate

3 months after radiotherapy

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de março de 2022

Conclusão Primária (Real)

30 de janeiro de 2024

Conclusão do estudo (Real)

30 de janeiro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

19 de fevereiro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de março de 2022

Primeira postagem (Real)

8 de março de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever